CTLA4 and pancreatitis: In nearly all the subgroups, we found the low overall heterogeneity of grade 1–5/3–5 pancreatitis, amylase, and lipase elevation incidence which displayed I2 values of 0.0%, but not in this subgroup (CTLA-4 inhibitor subgroup versus chemotherapy/placebo: I2 = 56.8%, p = 0.128).